TipRanks
Advertisement
Advertisement

INCY Stock Latest News

Incyte Reaches CMS Pact on Jakafi Medicaid Pricing
Company AnnouncementsIncyte Reaches CMS Pact on Jakafi Medicaid Pricing
18d ago
8K
INCY
Buy Rating Reaffirmed on Incyte as ‘734 Pancreatic Cancer Data Looms; 12-Month Price Target Reiterated at $150
PremiumRatings
Buy Rating Reaffirmed on Incyte as ‘734 Pancreatic Cancer Data Looms; 12-Month Price Target Reiterated at $150
23d ago
INCY
KDP, Ultragenyx, Incyte, ProQR, Aurinia Trending With Analysts
PremiumWeekend Updates
KDP, Ultragenyx, Incyte, ProQR, Aurinia Trending With Analysts
28d ago
KDP
AUPH
Incyte initiated with a Buy at Canaccord
PremiumThe Fly
Incyte initiated with a Buy at Canaccord
30d ago
INCY
Incyte Target Unchanged at $150 as Kapoor Reiterates Buy on Strong Early KRAS G12D Pancreatic Cancer Data
PremiumRatings
Incyte Target Unchanged at $150 as Kapoor Reiterates Buy on Strong Early KRAS G12D Pancreatic Cancer Data
30d ago
INCY
Matt Phipps Maintains Hold Rating on Incyte as Promising Early KRAS G12D PDAC Data Face Durability and Safety Uncertainties
PremiumRatingsMatt Phipps Maintains Hold Rating on Incyte as Promising Early KRAS G12D PDAC Data Face Durability and Safety Uncertainties
1M ago
INCY
Incyte ‘734 update likely to be ‘very competitive,’ says RBC Capital
Premium
The Fly
Incyte ‘734 update likely to be ‘very competitive,’ says RBC Capital
1M ago
INCY
RVMD
Incyte price target raised to $130 from $110 at Piper Sandler
Premium
The Fly
Incyte price target raised to $130 from $110 at Piper Sandler
1M ago
INCY
Incyte price target raised to $104 from $99 at Bernstein
PremiumThe Fly
Incyte price target raised to $104 from $99 at Bernstein
1M ago
INCY
Incyte Earnings Call: Growth Surges, Costs Climb
PremiumCompany Announcements
Incyte Earnings Call: Growth Surges, Costs Climb
1M ago
INCY
Incyte’s EXCALIBUR-ET2 Trial Targets a New Edge in Essential Thrombocythemia
PremiumCompany Announcements
Incyte’s EXCALIBUR-ET2 Trial Targets a New Edge in Essential Thrombocythemia
1M ago
INCY
Incyte price target raised to $137 from $121 at Mizuho
PremiumThe Fly
Incyte price target raised to $137 from $121 at Mizuho
2M ago
INCY
Incyte price target raised to $155 from $131 at Leerink
PremiumThe FlyIncyte price target raised to $155 from $131 at Leerink
2M ago
INCY
Analyst Reiterates Buy on Opzelura Strength, Keeps 12-Month Price Target Unchanged at $150
Premium
Ratings
Analyst Reiterates Buy on Opzelura Strength, Keeps 12-Month Price Target Unchanged at $150
2M ago
INCY
Incyte price target raised to $120 from $110 at JPMorgan
Premium
The Fly
Incyte price target raised to $120 from $110 at JPMorgan
2M ago
INCY
Damora Therapeutics price target raised to $40 from $35 at Wedbush
PremiumThe Fly
Damora Therapeutics price target raised to $40 from $35 at Wedbush
2M ago
DMRA
INCY
Incyte price target raised to $109 from $99 at RBC Capital
PremiumThe Fly
Incyte price target raised to $109 from $99 at RBC Capital
2M ago
INCY
Incyte price target raised to $130 from $112 at BMO Capital
PremiumThe Fly
Incyte price target raised to $130 from $112 at BMO Capital
2M ago
INCY
Incyte price target raised to $150 from $136 at Guggenheim
PremiumThe Fly
Incyte price target raised to $150 from $136 at Guggenheim
2M ago
INCY
Incyte Rally Caps Near-Term Upside; Ashwani Verma Reiterates Hold With Unchanged $113 Price Target
PremiumRatingsIncyte Rally Caps Near-Term Upside; Ashwani Verma Reiterates Hold With Unchanged $113 Price Target
2M ago
INCY
Incyte price target raised to $119 from $104 at Morgan Stanley
Premium
The Fly
Incyte price target raised to $119 from $104 at Morgan Stanley
2M ago
INCY
Incyte says EC approves Opzelura cream for treatment of AD
Premium
The Fly
Incyte says EC approves Opzelura cream for treatment of AD
2M ago
INCY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >